CRISPR TherapeuticsCRSP
About: Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Employees: 407
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 5 (+0) [Q3]
1.0% less ownership
Funds ownership: 70.8% [Q2] → 69.81% (-1.0%) [Q3]
2% less repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 129
8% less funds holding
Funds holding: 441 [Q2] → 406 (-35) [Q3]
14% less capital invested
Capital invested by funds: $3.25B [Q2] → $2.79B (-$454M) [Q3]
34% less call options, than puts
Call options by funds: $68.2M | Put options by funds: $103M
44% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 79
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
JMP Securities Silvan Tuerkcan 35% 1-year accuracy 18 / 51 met price target | 111%upside $86 | Market Outperform Reiterated | 20 Dec 2024 |
Chardan Capital Geulah Livshits 17% 1-year accuracy 8 / 48 met price target | 131%upside $94 | Buy Maintained | 10 Dec 2024 |
RBC Capital Luca Issi 27% 1-year accuracy 15 / 56 met price target | 30%upside $53 | Sector Perform Reiterated | 6 Nov 2024 |
Barclays Gena Wang 13% 1-year accuracy 4 / 30 met price target | 35%upside $55 | Equal-Weight Maintained | 6 Nov 2024 |
Needham Gil Blum 21% 1-year accuracy 34 / 164 met price target | 106%upside $84 | Buy Reiterated | 6 Nov 2024 |
Financial journalist opinion
Based on 14 articles about CRSP published over the past 30 days
